Selected research
Market Analysis & Forecast
Global Pharmacokinetic Testing Market Analysis and Forecast 2026-2032
Market perspective
The global Pharmacokinetic Testing market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Pharmacokinetic Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Pharmacokinetic Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Pharmacokinetic Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Pharmacokinetic Testing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Pharmacokinetic Testing include Certara, L.P., Evotec AG, Pacific BioLabs, GVK Biosciences Private Limited, SGS SA, LGC Limited, Pharmaceutical Product Development, LLC, Charles River Laboratories International, Inc. and Creative Bioarray, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Pharmacokinetic Testing, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Pharmacokinetic Testing, also provides the revenue of main regions and countries. Of the upcoming market potential for Pharmacokinetic Testing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Pharmacokinetic Testing revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pharmacokinetic Testing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Pharmacokinetic Testing revenue, projected growth trends, production technology, application and end-user industry.
Pharmacokinetic Testing Segment by Company
Certara, L.P.
Evotec AG
Pacific BioLabs
GVK Biosciences Private Limited
SGS SA
LGC Limited
Pharmaceutical Product Development, LLC
Charles River Laboratories International, Inc.
Creative Bioarray
Pharmacokinetic Testing Segment by Type
Oral Dissolution Testing (FDC)
Intravenous Titration Test (IVRT)
Cell Line In-house Testing (ICR)
Pharmacokinetic Testing Segment by Application
Hospital
Clinic
Research Institutions
Pharmacokinetic Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmacokinetic Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pharmacokinetic Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmacokinetic Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Pharmacokinetic Testing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Pharmacokinetic Testing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pharmacokinetic Testing revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral Dissolution Testing (FDC)
- Intravenous Titration Test (IVRT)
- Cell Line In-house Testing (ICR)
Applications
- Hospital
- Clinic
- Research Institutions
Companies covered
- Certara, L.P.
- Evotec AG
- Pacific BioLabs
- GVK Biosciences Private Limited
- SGS SA
- LGC Limited
- Pharmaceutical Product Development, LLC
- Charles River Laboratories International, Inc.
- Creative Bioarray
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Pharmacokinetic Testing Market by Type
- 1.2.1 Global Pharmacokinetic Testing Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Oral Dissolution Testing (FDC)
- 1.2.3 Intravenous Titration Test (IVRT)
- 1.2.4 Cell Line In-house Testing (ICR)
- 1.3 Pharmacokinetic Testing Market by Application
- 1.3.1 Global Pharmacokinetic Testing Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Clinic
- 1.3.4 Research Institutions
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Pharmacokinetic Testing Market Dynamics
- 2.1 Pharmacokinetic Testing Industry Trends
- 2.2 Pharmacokinetic Testing Industry Drivers
- 2.3 Pharmacokinetic Testing Industry Opportunities and Challenges
- 2.4 Pharmacokinetic Testing Industry Restraints
3 Global Growth Perspective
- 3.1 Global Pharmacokinetic Testing Market Perspective (2021-2032)
- 3.2 Global Pharmacokinetic Testing Growth Trends by Region
- 3.2.1 Global Pharmacokinetic Testing Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Pharmacokinetic Testing Market Size by Region (2021-2026)
- 3.2.3 Global Pharmacokinetic Testing Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Pharmacokinetic Testing Revenue by Players
- 4.1.1 Global Pharmacokinetic Testing Revenue by Players (2021-2026)
- 4.1.2 Global Pharmacokinetic Testing Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Pharmacokinetic Testing Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Pharmacokinetic Testing Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Pharmacokinetic Testing Key Players Headquarters & Area Served
- 4.4 Global Pharmacokinetic Testing Players, Product Type & Application
- 4.5 Global Pharmacokinetic Testing Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Pharmacokinetic Testing Market CR5 and HHI
- 4.6.3 2025 Pharmacokinetic Testing Tier 1, Tier 2, and Tier 3
5 Pharmacokinetic Testing Market Size by Type
- 5.1 Global Pharmacokinetic Testing Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Pharmacokinetic Testing Revenue by Type (2021-2032)
- 5.3 Global Pharmacokinetic Testing Revenue Market Share by Type (2021-2032)
6 Pharmacokinetic Testing Market Size by Application
- 6.1 Global Pharmacokinetic Testing Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Pharmacokinetic Testing Revenue by Application (2021-2032)
- 6.3 Global Pharmacokinetic Testing Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Certara, L.P.
- 7.1.1 Certara, L.P. Company Information
- 7.1.2 Certara, L.P. Business Overview
- 7.1.3 Certara, L.P. Pharmacokinetic Testing Revenue and Gross Margin (2021-2026)
- 7.1.4 Certara, L.P. Pharmacokinetic Testing Product Portfolio
- 7.1.5 Certara, L.P. Recent Developments
- 7.2 Evotec AG
- 7.2.1 Evotec AG Company Information
- 7.2.2 Evotec AG Business Overview
- 7.2.3 Evotec AG Pharmacokinetic Testing Revenue and Gross Margin (2021-2026)
- 7.2.4 Evotec AG Pharmacokinetic Testing Product Portfolio
- 7.2.5 Evotec AG Recent Developments
- 7.3 Pacific BioLabs
- 7.3.1 Pacific BioLabs Company Information
- 7.3.2 Pacific BioLabs Business Overview
- 7.3.3 Pacific BioLabs Pharmacokinetic Testing Revenue and Gross Margin (2021-2026)
- 7.3.4 Pacific BioLabs Pharmacokinetic Testing Product Portfolio
- 7.3.5 Pacific BioLabs Recent Developments
- 7.4 GVK Biosciences Private Limited
- 7.4.1 GVK Biosciences Private Limited Company Information
- 7.4.2 GVK Biosciences Private Limited Business Overview
- 7.4.3 GVK Biosciences Private Limited Pharmacokinetic Testing Revenue and Gross Margin (2021-2026)
- 7.4.4 GVK Biosciences Private Limited Pharmacokinetic Testing Product Portfolio
- 7.4.5 GVK Biosciences Private Limited Recent Developments
- 7.5 SGS SA
- 7.5.1 SGS SA Company Information
- 7.5.2 SGS SA Business Overview
- 7.5.3 SGS SA Pharmacokinetic Testing Revenue and Gross Margin (2021-2026)
- 7.5.4 SGS SA Pharmacokinetic Testing Product Portfolio
- 7.5.5 SGS SA Recent Developments
- 7.6 LGC Limited
- 7.6.1 LGC Limited Company Information
- 7.6.2 LGC Limited Business Overview
- 7.6.3 LGC Limited Pharmacokinetic Testing Revenue and Gross Margin (2021-2026)
- 7.6.4 LGC Limited Pharmacokinetic Testing Product Portfolio
- 7.6.5 LGC Limited Recent Developments
- 7.7 Pharmaceutical Product Development, LLC
- 7.7.1 Pharmaceutical Product Development, LLC Company Information
- 7.7.2 Pharmaceutical Product Development, LLC Business Overview
- 7.7.3 Pharmaceutical Product Development, LLC Pharmacokinetic Testing Revenue and Gross Margin (2021-2026)
- 7.7.4 Pharmaceutical Product Development, LLC Pharmacokinetic Testing Product Portfolio
- 7.7.5 Pharmaceutical Product Development, LLC Recent Developments
- 7.8 Charles River Laboratories International, Inc.
- 7.8.1 Charles River Laboratories International, Inc. Company Information
- 7.8.2 Charles River Laboratories International, Inc. Business Overview
- 7.8.3 Charles River Laboratories International, Inc. Pharmacokinetic Testing Revenue and Gross Margin (2021-2026)
- 7.8.4 Charles River Laboratories International, Inc. Pharmacokinetic Testing Product Portfolio
- 7.8.5 Charles River Laboratories International, Inc. Recent Developments
- 7.9 Creative Bioarray
- 7.9.1 Creative Bioarray Company Information
- 7.9.2 Creative Bioarray Business Overview
- 7.9.3 Creative Bioarray Pharmacokinetic Testing Revenue and Gross Margin (2021-2026)
- 7.9.4 Creative Bioarray Pharmacokinetic Testing Product Portfolio
- 7.9.5 Creative Bioarray Recent Developments
8 North America
- 8.1 North America Pharmacokinetic Testing Revenue (2021-2032)
- 8.2 North America Pharmacokinetic Testing Revenue by Type (2021-2032)
- 8.2.1 North America Pharmacokinetic Testing Revenue by Type (2021-2026)
- 8.2.2 North America Pharmacokinetic Testing Revenue by Type (2027-2032)
- 8.3 North America Pharmacokinetic Testing Revenue Share by Type (2021-2032)
- 8.4 North America Pharmacokinetic Testing Revenue by Application (2021-2032)
- 8.4.1 North America Pharmacokinetic Testing Revenue by Application (2021-2026)
- 8.4.2 North America Pharmacokinetic Testing Revenue by Application (2027-2032)
- 8.5 North America Pharmacokinetic Testing Revenue Share by Application (2021-2032)
- 8.6 North America Pharmacokinetic Testing Revenue by Country
- 8.6.1 North America Pharmacokinetic Testing Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Pharmacokinetic Testing Revenue by Country (2021-2026)
- 8.6.3 North America Pharmacokinetic Testing Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Pharmacokinetic Testing Revenue (2021-2032)
- 9.2 Europe Pharmacokinetic Testing Revenue by Type (2021-2032)
- 9.2.1 Europe Pharmacokinetic Testing Revenue by Type (2021-2026)
- 9.2.2 Europe Pharmacokinetic Testing Revenue by Type (2027-2032)
- 9.3 Europe Pharmacokinetic Testing Revenue Share by Type (2021-2032)
- 9.4 Europe Pharmacokinetic Testing Revenue by Application (2021-2032)
- 9.4.1 Europe Pharmacokinetic Testing Revenue by Application (2021-2026)
- 9.4.2 Europe Pharmacokinetic Testing Revenue by Application (2027-2032)
- 9.5 Europe Pharmacokinetic Testing Revenue Share by Application (2021-2032)
- 9.6 Europe Pharmacokinetic Testing Revenue by Country
- 9.6.1 Europe Pharmacokinetic Testing Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Pharmacokinetic Testing Revenue by Country (2021-2026)
- 9.6.3 Europe Pharmacokinetic Testing Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Pharmacokinetic Testing Revenue (2021-2032)
- 10.2 China Pharmacokinetic Testing Revenue by Type (2021-2032)
- 10.2.1 China Pharmacokinetic Testing Revenue by Type (2021-2026)
- 10.2.2 China Pharmacokinetic Testing Revenue by Type (2027-2032)
- 10.3 China Pharmacokinetic Testing Revenue Share by Type (2021-2032)
- 10.4 China Pharmacokinetic Testing Revenue by Application (2021-2032)
- 10.4.1 China Pharmacokinetic Testing Revenue by Application (2021-2026)
- 10.4.2 China Pharmacokinetic Testing Revenue by Application (2027-2032)
- 10.5 China Pharmacokinetic Testing Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Pharmacokinetic Testing Revenue (2021-2032)
- 11.2 Asia Pharmacokinetic Testing Revenue by Type (2021-2032)
- 11.2.1 Asia Pharmacokinetic Testing Revenue by Type (2021-2026)
- 11.2.2 Asia Pharmacokinetic Testing Revenue by Type (2027-2032)
- 11.3 Asia Pharmacokinetic Testing Revenue Share by Type (2021-2032)
- 11.4 Asia Pharmacokinetic Testing Revenue by Application (2021-2032)
- 11.4.1 Asia Pharmacokinetic Testing Revenue by Application (2021-2026)
- 11.4.2 Asia Pharmacokinetic Testing Revenue by Application (2027-2032)
- 11.5 Asia Pharmacokinetic Testing Revenue Share by Application (2021-2032)
- 11.6 Asia Pharmacokinetic Testing Revenue by Country
- 11.6.1 Asia Pharmacokinetic Testing Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Pharmacokinetic Testing Revenue by Country (2021-2026)
- 11.6.3 Asia Pharmacokinetic Testing Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Pharmacokinetic Testing Revenue (2021-2032)
- 12.2 SAMEA Pharmacokinetic Testing Revenue by Type (2021-2032)
- 12.2.1 SAMEA Pharmacokinetic Testing Revenue by Type (2021-2026)
- 12.2.2 SAMEA Pharmacokinetic Testing Revenue by Type (2027-2032)
- 12.3 SAMEA Pharmacokinetic Testing Revenue Share by Type (2021-2032)
- 12.4 SAMEA Pharmacokinetic Testing Revenue by Application (2021-2032)
- 12.4.1 SAMEA Pharmacokinetic Testing Revenue by Application (2021-2026)
- 12.4.2 SAMEA Pharmacokinetic Testing Revenue by Application (2027-2032)
- 12.5 SAMEA Pharmacokinetic Testing Revenue Share by Application (2021-2032)
- 12.6 SAMEA Pharmacokinetic Testing Revenue by Country
- 12.6.1 SAMEA Pharmacokinetic Testing Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Pharmacokinetic Testing Revenue by Country (2021-2026)
- 12.6.3 SAMEA Pharmacokinetic Testing Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst